Loading
A phase 3 trial testing D-0502 in HR-positive / HER2-negative breast cancer, now recruiting.
A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer is a phase 3 interventional study registered as NCT06954961, led by InventisBio, and recruiting on the registry. Official title: A Randomised, Parallel-controlled, Open-label, Multicenter Phase III Clinical Study to Compare the Efficacy and Safety of D-0502 With Fulvestrant in Patients With Previously Treated ER-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer. Planned enrolment is 640 participants (estimated). The study started in 2022-09-15 and primary completion is expected in 2026-11-30. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/